Last reviewed · How we verify
NCT04970979
Exercise Adherence in Home-based Cardiac Rehabilitation
trial testing survey in Coronary Artery Disease in 300 participants. Status unknown.
18 February 2022
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 18 July 2021 |
| Primary completion | 18 February 2022 |
| Estimated completion | 18 February 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- survey
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Peking University Third Hospital
Who can join
Under 75, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will investigate the influencing factors of exercise adherence of home-based cardiac rehabilitation in patients with coronary artery disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04970979
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of survey
Trials testing the same drug.
- NCT07340203 — Cross-Cultural Adaptation, Validity, and Reliability of the Wexner Questionnaire in Patients With Constipation · active not recruiting
- NCT07033390 — Monitor Orthopaedic Footwear Questionnaire (MOS) Validity and Reliability Study · enrolling by invitation
- NCT07012083 — Adherence to Anti-rabies Post-exposure Prophylactic Protocols · completed
- NCT06897865 — Nursing Students Education Virtual Reality Wound Care · not yet recruiting
- NCT06514443 — Barriers and Faciliators for Physical Activity in People With RMDs · not yet recruiting
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04970979 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 21 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04970979.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing